Controversy
Status:Open
Will Semaglutide Biosimilars or Generics Become Available in the US Market Before 2032?
UNLIKELYLIKELY
Claims
GLP1 Clinics"Generic semaglutide could reach the U.S. market as early as 2031 when the core compound patent expires, with authorized generics potentially arriving by 2028 or 2029 through negotiated agreements."May 09, 2026
scienceinsights.org"That [2032] is the earliest a generic or biosimilar version of Ozempic or Wegovy could reach the American market, and additional patents or legal challenges could push that date further out."Mar 10, 2026
NBC“Due to patent extensions, approved generic versions of semaglutide aren’t expected in the U.S. until at least the end of 2031.”May 13, 2026
Reuters"Its patent on semaglutide, the key ingredient in Wegovy and its diabetes drug Ozempic, is set to expire in less than two years in China compared to in 2031 in Europe and Japan and in 2032 in the U.S, and local drugmakers are racing to develop generic or biosimilar versions."Jun 22, 2026
GLPSpot"The earliest expected generic date is 2031 for Ozempic and 2032 for Wegovy, though patent litigation could change this timeline."Apr 10, 2026
Noom"For people in the United States, generic semaglutide is unlikely before 2031 at the earliest — that’s when the primary U.S. compound patent expires."May 14, 2026
Healthline"A generic version of Wegovy is not currently available in the United States due to patents held by the manufacturer, Novo Nordisk, that may remain in effect until 2041."May 05, 2026
Berkeley Lovelace Jr."Thanks largely to loopholes in the U.S. patent system, Americans aren’t expected to get generic forms of semaglutide, the drug in Novo Nordisk’s Ozempic and Wegovy, until at least the end of 2031."May 13, 2026
Telehealth Ally"No generic Ozempic will be available in the US before 2031–2032; semaglutide requires a biosimilar, not a generic."Apr 29, 2026
Peptide News Digest"The first US ANDAs (Abbreviated New Drug Applications) for generic semaglutide are expected to be filed shortly before the patent expiry date, with tentative approvals possible mid-2031 and commercial launches in early 2032."May 15, 2026
Morning Star"Several countries will soon get generic versions of Wegovy and Ozempic, but that won't happen in the U.S. until at least 2032. "May 22, 2026
Markman Advisors LLC"The chart suggests that generic Ozempic is likely to enter some time in 2032."Feb 07, 2025
Columbia Science and Technology Law Review (STLR)"While Novo Nordisk’s patent in the U.S. is set to expire in 2032, its patents in other markets are set to expire much sooner."Jun 22, 2026
Form BlendsThe practical date for generic competition depends on formulation type, with oral generics possible by 2027 and injectable versions by 2031-2032.May 01, 2026
MedxDrg"The earliest possible entry for a generic is widely cited as December 2031, though ongoing legal challenges and different expiration dates for various patents could further delay or even accelerate availability."Jul 03, 2026
PatentCliffIn the United States, full generic availability is unlikely before 2031-2032 due to the layered patent strategy.Jun 23, 2026
Aurisco Pharmaceutical“SEMAGLUTIDE’S GENERIC ENTRY STARTS IN 2026 IN SEVERAL LARGE MARKETS, BUT IS UNLIKELY IN THE U.S. AND EUROPE BEFORE 2031."May 28, 2026
Pandameds"The short answer is that U.S. patients are unlikely to see an FDA-approved generic semaglutide injection before December 2031 at the earliest. "May 26, 2026
Meto Health"The U.S. timeline is realistically the early 2030s at the earliest — with many analysts projecting 2033–2036 under current patent conditions."Jun 09, 2026
© 2026 Improve the News Foundation. All rights reserved.Version 7.16.0
© 2026 Improve the News Foundation.
All rights reserved.
Version 7.16.0